SCLC-Y, initially found in 5–10% of SCLC tumors, more commonly in tumors of mixed histology previously characterized with high YAP1 expression, enriched RB wild-type status, and low or absent expression of ASCL1, and NEUROD1 [22], was considered to be of poor prognosis, with a tendency to chemoresistance. This evidence concerns the gene YAP1 and small cell lung carcinoma.